Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents

US10039845B2 · kind B2 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Martin G. Pomper · Baltimore, US
• Sangeeta Ray · Ellicott City, US
• Ronnie C. Mease · Fairfax, US
• Catherine A. Foss · Baltimore, US

Key dates

• Filing date: Jun 30, 2017
• Grant date: Aug 7, 2018
• Expiry date: Jun 30, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.